ABSTRACT
Specialists have the ethical obligation to promote smoking cessation using evidence-based therapeutic strategies. In the context of the growing popularity of the electronic cigarettes (ECs), the smokers asking us about it and we must be ready to provide expert advice. With the evidence available to date we must be cautious in recommending of the smokers to use ECs for smoking cessation because these have not proven superiority over drugs used for smoking cessation approved by the Food and Drug Administration (FDA), ECs are not FDA approved, short-term safety data shows that they cause airway reactivity and health risk of exposure to ECs in the long term is unknown. Before the ECs to occupy a place in the standard clinical approaches for the treatment of tobacco addiction longer needed more data about their safety clinical and regulatory of their use.
